Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is exhibiting promising outcomes in initial human studies. Current examination implies that retatrutide may offer substantial benefits for people with obesity, particularly regarding weight loss and glucose control . Subseque